Artisan Partners Limited Partnership Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Artisan Partners Limited Partnership increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 36.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 337,234 shares of the medical equipment provider’s stock after purchasing an additional 89,468 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.49% of Lantheus worth $30,169,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in LNTH. State of New Jersey Common Pension Fund D increased its position in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 129 shares in the last quarter. Avantax Advisory Services Inc. raised its position in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. UMB Bank n.a. boosted its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Finally, Aurora Investment Counsel grew its position in Lantheus by 0.8% during the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock worth $1,718,000 after purchasing an additional 146 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $96.16 on Friday. The stock has a market capitalization of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38. The firm’s 50 day simple moving average is $93.21 and its 200-day simple moving average is $96.44. Lantheus Holdings, Inc. has a 12 month low of $58.16 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LNTH. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.